Prosight Management
Latest statistics and disclosures from Prosight Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are STTK, ADCT, GLPG, MGTX, KURA, and represent 38.90% of Prosight Management's stock portfolio.
- Added to shares of these 10 stocks: ROIV (+$20M), BBIO (+$18M), CYTK (+$17M), STTK (+$14M), KIDS (+$12M), GH (+$9.7M), KELYA (+$8.7M), ADCT (+$7.4M), ERAS (+$7.0M), GLPG (+$6.5M).
- Started 22 new stock positions in AVRO, BBIO, MRVI, CRBP, PRVA, PFE, COGT, TXG, CYTK, RLAY. ABSI, ZBH, ROIV, OVID, GH, IMVT, MURA, KELYA, VKTX, KIDS, LENZ, AGIO.
- Reduced shares in these 10 stocks: PCRX (-$33M), HUM (-$32M), KURA (-$21M), ORIC (-$16M), NARI (-$8.5M), INSP (-$7.9M), NBIX (-$6.8M), QDEL (-$6.2M), NSTGQ (-$5.9M), .
- Sold out of its positions in AGL, ELUT, CNC, CHE, CMPX, QDEL, DSGN, EOLS, Graphite Bio, HUM. IRTC, NARI, INSP, LBPH, MASI, NSTGQ, ORIC, PEN, TDOC.
- Prosight Management was a net seller of stock by $-17M.
- Prosight Management has $360M in assets under management (AUM), dropping by 13.92%.
- Central Index Key (CIK): 0001617201
Tip: Access up to 7 years of quarterly data
Positions held by Prosight Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Prosight Management
Prosight Management holds 44 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Shattuck Labs (STTK) | 9.3 | $33M | +75% | 3.7M | 8.94 |
|
| Adc Therapeutics Sa SHS (ADCT) | 8.8 | $32M | +30% | 7.1M | 4.49 |
|
| Galapagos Nv Spon Adr (GLPG) | 8.3 | $30M | +27% | 932k | 32.20 |
|
| Meiragtx Holdings (MGTX) | 6.8 | $24M | 4.0M | 6.07 |
|
|
| Kura Oncology (KURA) | 5.7 | $21M | -50% | 960k | 21.33 |
|
| Roivant Sciences SHS (ROIV) | 5.5 | $20M | NEW | 1.9M | 10.54 |
|
| Bridgebio Pharma (BBIO) | 5.1 | $18M | NEW | 590k | 30.92 |
|
| Cytokinetics Com New (CYTK) | 4.8 | $17M | NEW | 245k | 70.11 |
|
| Medtronic SHS (MDT) | 4.4 | $16M | +20% | 180k | 87.15 |
|
| Orthopediatrics Corp. (KIDS) | 3.4 | $12M | NEW | 418k | 29.16 |
|
| Mirum Pharmaceuticals (MIRM) | 3.2 | $12M | +31% | 465k | 25.12 |
|
| Guardant Health (GH) | 2.7 | $9.7M | NEW | 470k | 20.63 |
|
| Kelly Svcs Cl A (KELYA) | 2.4 | $8.7M | NEW | 349k | 25.04 |
|
| Abcellera Biologics (ABCL) | 2.3 | $8.1M | -26% | 1.8M | 4.53 |
|
| Erasca (ERAS) | 2.1 | $7.5M | +1282% | 3.7M | 2.06 |
|
| BioCryst Pharmaceuticals (BCRX) | 2.0 | $7.1M | -41% | 1.4M | 5.08 |
|
| Immunovant (IMVT) | 1.8 | $6.3M | NEW | 195k | 32.31 |
|
| Pfizer (PFE) | 1.7 | $6.0M | NEW | 215k | 27.75 |
|
| Alkermes SHS (ALKS) | 1.6 | $5.8M | +230% | 215k | 27.07 |
|
| Universal Hlth Svcs CL B (UHS) | 1.5 | $5.5M | -26% | 30k | 182.46 |
|
| Maravai Lifesciences Hldgs I Com Cl A (MRVI) | 1.4 | $5.2M | NEW | 600k | 8.67 |
|
| Zymeworks Del (ZYME) | 1.2 | $4.3M | +286% | 411k | 10.52 |
|
| Prothena Corp SHS (PRTA) | 1.2 | $4.2M | +35% | 171k | 24.77 |
|
| Neurocrine Biosciences (NBIX) | 1.2 | $4.2M | -61% | 31k | 137.92 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 1.1 | $3.9M | NEW | 101k | 39.24 |
|
| Relay Therapeutics (RLAY) | 1.0 | $3.7M | NEW | 450k | 8.30 |
|
| Cogent Biosciences (COGT) | 1.0 | $3.7M | NEW | 556k | 6.72 |
|
| Option Care Health Com New (OPCH) | 0.9 | $3.4M | -54% | 100k | 33.54 |
|
| Viking Therapeutics (VKTX) | 0.9 | $3.2M | NEW | 39k | 82.00 |
|
| Dex (DXCM) | 0.9 | $3.2M | -63% | 23k | 138.70 |
|
| Barrett Business Services (BBSI) | 0.8 | $3.0M | +12% | 24k | 126.72 |
|
| Ovid Therapeutics (OVID) | 0.8 | $3.0M | NEW | 983k | 3.05 |
|
| Pacira Pharmaceuticals (PCRX) | 0.8 | $2.8M | -92% | 94k | 29.22 |
|
| Zimmer Holdings (ZBH) | 0.7 | $2.5M | NEW | 19k | 131.98 |
|
| Mural Oncology Pub Ord Shs (MURA) | 0.5 | $2.0M | NEW | 400k | 4.89 |
|
| Lenz Therapeutics (LENZ) | 0.4 | $1.5M | NEW | 65k | 22.33 |
|
| 10x Genomics Cl A Com (TXG) | 0.3 | $1.1M | NEW | 30k | 37.53 |
|
| Biomea Fusion (BMEA) | 0.3 | $1.1M | -20% | 75k | 14.95 |
|
| Nuvation Bio Com Cl A (NUVB) | 0.3 | $910k | -76% | 250k | 3.64 |
|
| Privia Health Group (PRVA) | 0.2 | $882k | NEW | 45k | 19.59 |
|
| Kezar Life Sciences (KZR) | 0.2 | $869k | -79% | 964k | 0.90 |
|
| Agios Pharmaceuticals (AGIO) | 0.2 | $731k | NEW | 25k | 29.24 |
|
| Avrobio Ord (AVRO) | 0.2 | $725k | NEW | 567k | 1.28 |
|
| Absci Corp (ABSI) | 0.0 | $142k | NEW | 25k | 5.68 |
|
Past Filings by Prosight Management
SEC 13F filings are viewable for Prosight Management going back to 2017
- Prosight Management 2024 Q1 filed May 15, 2024
- Prosight Management 2023 Q3 filed Nov. 14, 2023
- Prosight Management 2023 Q2 filed Aug. 14, 2023
- Prosight Management 2023 Q2 restated filed Aug. 14, 2023
- Prosight Management 2023 Q1 filed May 12, 2023
- Prosight Management 2022 Q4 filed Feb. 14, 2023
- Prosight Management 2022 Q3 filed Nov. 14, 2022
- Prosight Management 2022 Q2 filed Aug. 12, 2022
- Prosight Management 2022 Q1 filed May 16, 2022
- Prosight Management 2021 Q4 filed Feb. 14, 2022
- Prosight Management 2021 Q3 filed Nov. 12, 2021
- Prosight Management 2021 Q2 filed Aug. 13, 2021
- Prosight Management 2021 Q1 filed May 14, 2021
- Prosight Management 2020 Q4 filed Feb. 12, 2021
- Prosight Management 2020 Q3 filed Nov. 13, 2020
- Prosight Management 2020 Q2 filed Aug. 14, 2020